iBiopsy®: Promising Results on a Preliminary Study to Identify the Severity of the Disease in Patients With Non-Alcoholic Steatohepatitis (NASH)

According to the World Health Organization (WHO), Non-Alcoholic Fatty Liver Disease (NAFLD) is a pandemic affecting 25% of the global population1.